A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)

Fernando C. Maluf, Fabio A. Schutz, Eduardo H. Cronemberger, Murilo de A. Luz, Suelen P. S. Martins, David Q. B. Muniz, Diogo A. Bastos, Flavio M. Cárcano, Oren Smaletz, Andrey Soares, Fábio A. Peixoto, Andrea J. Gomes, Felipe M. Cruz, Fabio A. Franke, Daniel Herchenhorn, Telma M. dos Santos, Vanessa de C. Fabricio, Rosemarie Gidekel, Gustavo Werutsky, Rafaela G. de Jesus, Vinicius C. Souza, André P. Fay

DOI: https://doi.org/10.1016/j.ejca.2021.08.032

Full link: https://www.sciencedirect.com/science/article/pii/S0959804921005591